Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of maribateol a as preparation of medicine for treating ischemic brain injury

A technology of ischemic brain injury and butyrol, which is applied in the application field of maributol A as a drug for the treatment of ischemic brain injury, can solve the problems of increased bleeding risk, many contraindications, time window restrictions, etc., and achieve improvement Effects on brain function after ischemia

Active Publication Date: 2017-03-08
THE AFFILIATED DRUM TOWER HOSPITAL MEDICAL SCHOOL OF NANJING UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Before the present invention, the current clinical treatment of ischemic brain injury drugs mainly divided into the following categories: 1) thrombolytic drugs: alteplase (Alteplase), urokinase (Urokinase) etc., these drugs can promote fibrin degradation , but increases the risk of intracranial hemorrhage, and has a strict time window
2) Antiplatelet: such as Aspirin and Clopidogrel, the anti-inflammatory effects of these drugs need to be studied, and they can also increase the risk of bleeding
3) Drugs for reducing intracranial pressure by dehydration: such as Mannitol, which can rapidly dehydrate and reduce intracranial pressure, but there are many contraindications
4) Neurotrophic drugs: such as Piracetam and Edaravone, these drugs damage the cranial nerves, but the efficacy still needs further clinical verification
One of the prevention and treatment strategies for ischemic brain injury is to regulate the post-ischemic inflammatory response, but there is still a lack of such drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of maribateol a as preparation of medicine for treating ischemic brain injury
  • Application of maribateol a as preparation of medicine for treating ischemic brain injury
  • Application of maribateol a as preparation of medicine for treating ischemic brain injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] In vivo studies demonstrated that MA has a therapeutic effect on MCAO mice:

[0066] The middle cerebral artery infarction model on one side of C57L / B6 mice was established by suture method, that is, the MCAO model, and treated with MA tail vein injection. MA has been shown to have a protective effect against ischemic brain injury through behavioral studies.

[0067] 1) Materials and methods

[0068] The MCAO mouse model was established by thread embolization method, and the experiment was randomly divided into 3 groups: sham group, MCAO group, MCAO+MA (Nanjing University, Nanjing, China) 10 mg / kg group, 12 mice in each group, and tail vein injection .

[0069] Neurological Severity Severity (NSS) Scoring: The Modified Neurological Severity Severity Score (mNSS) was used to score the neurological deficit of mice. The total score of mNSS is 18 points, 1-6 is divided into mild injury, 7-12 is divided into moderate injury, and 13-18 is divided into severe injury.

[00...

Embodiment 2

[0077] In vitro studies demonstrated that MA improves cell viability after OGD and promotes the differentiation of BV2 cells into M2 type:

[0078] 1) Materials and methods

[0079] Microglioma cell culture: Microglioma cells, namely BV2 cells, were purchased from ATCC in the United States and grown in a medium containing 10% fetal bovine serum, 2 mmol / L L-glutamine, penicillin (100 U / ml) and streptomycin (100 μg / ml) DMEM high glucose medium, 37°C, 5% CO2 incubator.

[0080] Viability detection of BV2 cells: BV2 cells were treated with OGD, and cells were treated with different concentrations of MA. Cell viability was detected by the tetramethylazolium salt colorimetric method (MTT method). Add MTT to 100 μl of culture solution / well, continue culturing for 4 hours in an incubator at 37°C, 5% CO2, then pour out all the culture solution, add 100 μl of DMSO solution to each well, shake on a shaker until the blue-purple crystals are completely dissolved, and the enzyme The sta...

Embodiment 3

[0088] In vivo studies have demonstrated that MA promotes the differentiation of microglia towards the replacement type and attenuates the post-ischemic inflammatory response:

[0089] 1) Materials and methods

[0090] Detection of mRNA expression levels of inflammatory factors: After MCAO in mice, MA was injected into the tail vein at the time of ischemia for 2 hours and reperfusion. The brains were removed at 6, 24, 48 and 96 hours after reperfusion, and the expression levels of inflammatory factors were measured by RT-PCR, the method was the same as before.

[0091] Detection of M2 type markers: After MCAO of mice, cortical tissues of mice in each group were taken, and total RNA was extracted in each group.

[0092] The specific method is the same as above.

[0093] Determination of the activation state of microglial cells in the mouse cortex tissue: 24 hours after the mouse MCAO was reperfused, the whole brain tissue of each group of mice was collected after perfusion wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of maributol A as a medicine for treating ischemic brain injury. The present invention prepares maributol A into an injection preparation, the molecular formula of the maributol A is C28H2007, and the molecular weight is 468KD. The invention overcomes the respective defects of the existing thrombolytic drugs, anti-platelet aggregation drugs, dehydrating intracranial pressure-lowering drugs and neurotrophic drugs in the treatment of ischemic brain injury diseases. The present invention is a small molecular compound, which can be used for injection, can pass through the blood-brain barrier, and act on the pathological process of ischemic brain injury, which is in line with the current decision-making of developing drugs for treating ischemic brain injury, that is, to first improve brain function after ischemia , secondly, promote the differentiation of microglial cells to the replacement type to reduce the post-ischemic inflammatory response, and regulate the differentiation of microglial cells by acting on PPARγ.

Description

technical field [0001] The invention belongs to the technical field of biopharmaceuticals, and in particular relates to the application of maributol A as a medicine for treating ischemic brain injury. Background technique [0002] Ischemic stroke refers to the disorder of blood supply to the brain caused by various reasons, leading to brain tissue ischemia, hypoxic necrosis, and corresponding neurological deficits. It has the characteristics of high morbidity, high fatality rate, high disability rate, poor prognosis and easy recurrence, which brings heavy burden to family and society. Ischemic brain injury is an important factor affecting the prognosis of ischemic stroke. There are two main states of activation of microglia during cerebral ischemia: classical activation state (classical activation, M1 type) and alternative activation state (alternative activation, M2 type). The main markers of the former are MCP-1, lL-6, TNF-α, iNOS, COX-2 and some cytotoxic factors, which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/343A61P9/10A61P29/00
Inventor 徐运潘洁谭仁祥戈惠明
Owner THE AFFILIATED DRUM TOWER HOSPITAL MEDICAL SCHOOL OF NANJING UNIV